Comparative Pharmacology
Head-to-head clinical analysis: MECLOFENAMATE SODIUM versus TOLECTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLOFENAMATE SODIUM versus TOLECTIN.
MECLOFENAMATE SODIUM vs TOLECTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis.
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
400-600 mg orally three times daily; maximum 1.8 g/day.
None Documented
None Documented
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
Terminal half-life approximately 5-6 hours; clinical context: dosing every 6-8 hours required due to relatively short half-life; steady-state achieved within 24-30 hours.
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Renal (90-95% as unchanged drug and metabolites, primarily glucuronide conjugates); biliary/fecal (minor, <5%).
Category C
Category C
NSAID
NSAID